<DOC>
	<DOC>NCT01717625</DOC>
	<brief_summary>This study is multicentered, prospective, randomized, opened, parallel, intervention study. The aim of this study is to evaluate the efficacy and safety of Montelukast sodium in the prevention of bronchopulmonary dysplasia (BPD) in preterm infant, below 32weeks gestational age. The investigators evaluate the first effectiveness through the morbidity and mortality of bronchopulmonary dysplasia. And then, the investigators evaluate the second effectiveness through the oxygen index, the usage of mechanical ventilator about taking medicine after 2 Weeks, Oxygen Utilization After 4 Weeks, Proinflammatory Cytokine through the bronchial lavage fluid.</brief_summary>
	<brief_title>The Efficacy and Safety of Montelukast Sodium in the Prevention of Bronchopulmonary Dysplasia</brief_title>
	<detailed_description />
	<mesh_term>Birth Weight</mesh_term>
	<mesh_term>Bronchopulmonary Dysplasia</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Preterm infants born at less than 32 weeks Birth 14 days after, oxygen or artificial ventilation who are using patient more than 20cal/kg/d by enteral feeding written consent of the parents congenital anomaly cardiovascular collapse investigator's opinion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>10 Weeks</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>montelukast</keyword>
	<keyword>BPD</keyword>
	<keyword>singulair</keyword>
	<keyword>prematurity</keyword>
</DOC>